About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
(C) 2024 MINKABU THE INFONOID, Inc.

Cyfuse Biomedical K.K.(4892) Financial Results

4892
TSE Growth
Cyfuse Biomedical K.K.
438
JPY
-14
(-3.10%)
Dec 23, 3:30 pm JST
2.79
USD
Dec 23, 1:30 am EST
Result
PTS
outside of trading hours
ー
ー
Summary Chart Historical News Financial Result
Current Period Guidance
Annual
Result
Guidance History
Growth Rate
Profitability
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2020 ＊ 137 -372 -327 -329 -658.3 0 ー J-GAAP
Dec, 2021 ＊ 708 70 144 142 285.5 0 ー J-GAAP
Dec, 2022 374 -425 -433 -473 -178.1 0 Feb 14, 2023 J-GAAP
Dec, 2023 61 -697 -586 -589 -75.4 0 Feb 14, 2024 J-GAAP
Dec, 2024 Guidance 60 -926 -901 -904 -111.1 0 Nov 14, 2024 J-GAAP
YoY -1.6% -32.9% -53.8% -53.5% -47.3%
All-Time High
Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS
Record 708 70 144 142 285.5
Fiscal Year Dec, 2021 Dec, 2021 Dec, 2021 Dec, 2021 Dec, 2021
Second Half
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2022 42 -329 -357 -359 -135.2 0 Feb 14, 2023 J-GAAP
Jul - Dec, 2023 43 -334 -224 -225 -28.8 0 Feb 14, 2024 J-GAAP
Jul - Dec, 2024 Guidance 42 -478 -456 -457 -56.2 0 Nov 14, 2024 J-GAAP
YoY -2.3% -43.1% -103.6% -103.1% -95.0%
Cash Flow
Annual
Fiscal Year Operating Profit Fee Cash Flow Operating Cash Flow Investing Cash Flow Financial Cash Flow Cash & Equivalents Cash Ratio Accounting Standards
Dec, 2021 70 111 161 -50 229 1,613 60.96 J-GAAP
Dec, 2022 -425 -833 -403 -430 2,658 3,437 71.38 J-GAAP
Dec, 2023 -697 -581 -562 -19 18 2,873 68.18 J-GAAP
Actual Performance and Financial Trends
Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jan - Sep, 2022 340 -249 -232 -272 -193.3 ー ー J-GAAP
Jan - Sep, 2023 29 -528 -532 -534 -68.5 ー Nov 14, 2023 J-GAAP
Jan - Sep, 2024 26 -674 -662 -664 -82.8 ー Nov 14, 2024 J-GAAP
YoY -10.3% -27.7% -24.4% -24.3% -20.9%
Quarterly Results
Result
Growth Rate
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2022 34 -176 -201 -201 -75.7 -517.6 Feb 14, 2023 J-GAAP
Jan - Mar, 2023 7 -172 -167 -168 -21.6 -2,457.1 May 15, 2023 J-GAAP
Apr - Jun, 2023 11 -191 -195 -196 -25.2 -1,736.4 Aug 14, 2023 J-GAAP
Jul - Sep, 2023 11 -165 -170 -170 -21.8 -1,500.0 Nov 14, 2023 J-GAAP
Oct - Dec, 2023 32 -169 -54 -55 -7.0 -528.1 Feb 14, 2024 J-GAAP
Jan - Mar, 2024 10 -229 -223 -224 -28.4 -2,290.0 May 15, 2024 J-GAAP
Apr - Jun, 2024 8 -219 -222 -223 -28.0 -2,737.5 Aug 14, 2024 J-GAAP
Jul - Sep, 2024 8 -226 -217 -217 -27.1 -2,825.0 Nov 14, 2024 J-GAAP
YoY -27.3% -37.0% -27.6% -27.6% -24.1%
All-Time High Quarterly Results
Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS
Record 34 -153 -54 -55 -7.0
Fiscal Year Dec, 2022 Sep, 2022 Dec, 2023 Dec, 2023 Dec, 2023
Key Balance Sheet Figures
Fiscal Year BPS Equity Ratio Total Asset Equity Retained Earnings Interest-Bearing Debt Ratio Announce Accounting Standards
Dec, 2021 -2,591,955.00 71.8 2,646 1,899 -922 0.30 ー J-GAAP
Dec, 2022 484.88 78.3 4,815 3,769 -1,396 0.24 Feb 14, 2023 J-GAAP
Dec, 2023 405.71 76.0 4,214 3,202 -1,986 0.29 Feb 14, 2024 J-GAAP
Jan - Sep, 2024 ー 73.5 3,656 2,688 -2,650 0.30 Nov 14, 2024 J-GAAP